In lung cancer, an attempt to enhance anti-PD-1 therapy in NSCLC by depleting myeloid-derived suppressor cells with gemcitabine was prematurely terminated because of insufficient data collected; another clinical trial of TQB2928 monoclonal antibody promoting macrophage phagocytosis of tumor cells in combination with a third-generation EGFR TKI for advanced NSCLC is now recruiting. Here, EGFR is linked to non-small cell lung carcinoma.